Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026
Galectin Therapeutics Inc GALT
$3.41
▼ -1.45%
($-0.05)
📅 Earnings This Week
Open
$3.45
Prev Close
$3.46
Day Range
$3.30 – $3.53
52W Range
$2.03 – $7.13
Market Cap
$348.94M
Beta
0.60
EPS (TTM)
$-0.43
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2002-09-04 |
| Shares Out. | 100,850,000 |
| Website | galectintherapeutics.com/ ↗ |
| Phone | 16786203186 |
| Employees | 9 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$9.1M |
| Free Cash Flow | -$15.9M |
| Total Assets | $14.8M |
| Total Liabilities | $151.7M |
| Equity | -$138.6M |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Galectin Therapeutics Inc is a publicly traded company under the ticker symbol GALT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-11-01)